DOCSLIB.ORG

OP Ed: Another Victim of the Coronavirus: TRUTH (And a Not-To-Forget Lesson for People in Our Business)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
OP Ed: Another Victim of the Coronavirus: TRUTH (And a Not-To-Forget Lesson for People in Our Business) OP Ed: Another Victim Of The Coronavirus: TRUTH (And a Not-To-Forget Lesson For People In Our Business) Arthur Solomon, Public Relations Consultant The deadly coronavirus hates people. It has separated people from their families. It has separated people from their friends. It has caused massive unemployment. It frightens people. It is also responsible for an increase in hate messages on social media, targeting all minority populations, ranging from African-Americans, to Asian-Americans to religious Americans who practice Orthodox Judaism and to Jews who don’t. It has destroyed our way of living. The virus makes people very ill. Worst of all it kills people. But there is also a victim that was only made possible with the assistance of humans – TRUTH. President Trump’s revisionist remarks about the coronavirus, which is happening as I write this, on April 26, continues. The result: For many Americans is there is no TRUTH. And politics and the media have played a large part in aiding the virus to put TRUTH on life support. While TRUTH had been ill since January, it took a sudden turn for the worse in the U.S. on February 28, during a rally in South Carolina, when President Trump described the virus as a Democratic “hoax.” Other presidential remarks like saying, anyone who wants a test can get one; there are plenty of PPE supplies; doctors and nurses are hording them; we have the situation under control; his hawking of medicines for people infected with the disease as if he was a medical scientist, and his contradictory remarks about blaming the coronavirus on China, to name a few of the president’s comments, all added to put TRUTH in a grave condition. On January 22, President Trump, in an interview on CNBC’s “Squawk Box,” surprised everyone by using his previously unknown experience as an epidemiologist by describing the coronavirus as “one person coming in from China.” We have it totally under control. “It’s going to be just fine.” Never a believer in what scientists say, the president, on April 23, shocked the medical world and disinfectant manufacturers by asking medical researchers if injecting the sanitizers into people’s body might kill the virus. The president’s remarks caused Lysol, on April 24, to issue the following statement, in part: “As a global leader in health and hygiene products, we must be clear that under no circumstance should our disinfectant products be administered into the human body (through injection, ingestion or any other route),” Also on April 24, The Food and Drug Administration (FDA) issued a warning against using hydroxychloroquine, the anti- malaria drug that President Trump has suggested, to treat coronavirus outside of a hospital or drug trial. The FDA said, “The drugs hydroxychloroquine and chloroquine can cause dangerous abnormalities in heart rhythm in coronavirus patients, and should be used only in clinical trials or hospitals where patients can be closely monitored for heart problems” The president often says, “What do you have to lose? When he pretends to be a medical scientist by touting his Common Sense Degree from Trump University, the answer is people’s lives. What finally moved TRUTH to the intensive care unit were the comments of Trump’s lackeys, on his staff and in the media. For weeks before Trump declared a national emergency TV personalities on Fox News played down the seriousness of the coronavirus. They support anything the president says. It’s safe to assume (even though assuming is a “no-no” for serious journalists) that many of Fox’s viewers have been infected with the virus because they believe the Fox News opinion entertainers version of accuracy. Many viewers also probably died. And for those illnesses and deaths Fox management and commentators are responsible. (How they look themselves in a mirror is beyond me. They are as guilty of causing illnesses and deaths as is Trump and his staff lackeys. Maybe more so, because Fox News parrot’s what Trump says on various programs throughout the day and evening, with no fact checking as major publications do.) When the president accuses the media of reporting “fake news,” he should be pointing fingers at Laura Ingraham, who for weeks promoted the malaria drug hydroxychloroquine as a cure for coronavirus illness, along with her Fox News colleagues Tucker Carlson and Sean Hannity. During a discussion about the anti- malaria drug on his “Tucker Carlson Tonight” program, the host introduced Gregory Rigano as an advisor to the Stanford University School of Medicine. Stanford said Rigano has no affiliation with the school. Rigano also touted the drug on Ms. Ingraham’s program. A prime example of “fake news,” which the president disregarded while claiming that accurate news reports were “fake news.” (Media Matters For America reported, “During a two-week span between March 23 and April 6, Fox hosts and guests promoted hydroxychloroquine nearly 300 times. “Of these nearly 300 mentions, the vast majority came from four Fox shows: The Ingraham Angle(84 promotional mentions), Fox & Friends (76, including Fox & Friends First and Fox & Friends Weekend), Hannity (53), and Tucker Carlson Tonight (22).”) But the New York Times reported on April 25, when Fox’s prime time commentators, the most closely watched shows on Fox, had a chance to warn viewers against ingesting disinfectants as a cure for coronavirus, as the president had mentioned, they sidestepped that matter entirely on Thursday, (April 23) said the article. Of course, Ingraham, Hannity and Carlson aren’t the only Fox entertainers to earn the title of Trump lackeys. On “The Five” telecast on April 24, Greg Gutfeld defended Trump’s statement about how a disinfectant might help in curing the coronavirus by saying, “how could anyone believe that Trump meant it when he said people should inject Clorox into their bodies.” Also Dana Perino said the president wasn’t suggesting that people should drink bleach. (What about injecting it, Ms. Perino?) And as usual, as she does on all her “Media Buzz” appearances, another lackey, Mollie Hemingway, a senior editor at The Federalist, bashed the media’s coverage of Trump on the April 26 program. Whether he meant it or not Trump’s remarks showed the danger of his delving into medical issues. Maryland’s hotline received more than 100 calls about using a disinfectant after the president’s comment. And The Maryland Emergency Management Agency issued a warning for people not to ingest or inject disinfectant on social media shortly after Trump suggested doctors could study whether disinfectants could be injected or ingested to fight coronavirus. In Washington state, officials urged people not to consume laundry detergent capsules. In New York City, the Daily News reported that the Poison Control Center saw 30 cases of “exposure to Lysol, bleach and other cleaners in 18 hours after Trump’s suggestion” that cleaning products might be used to treat coronavirus. (April 24 was not a good day, scientifically speaking, for Trump, and he refused to take questions after making his opening remarks at his daily presser.) A headline on CNBC on March 17 said, “Trump dismissed coronavirus pandemic worry in January — now claims he long warned about it.” But that didn’t prevent the lackeys on the president’s staff (including Dr. Jerome Adams, the Surgeon General, who fails to correct the president’s pseudo science medical statements) to pretend that everything Trump says, along with his Fox News sycophants, about the virus is handed down to him from God. Led by chief lackey Vice President Pence, the president’s other lackeys thank him for his leadership almost every time Trump takes a breath. Prominent among them are Attorney General William Barr, the president’s lawyer, and Robert C. O’Brien, the White House national security advisor. On April 9, after the president said he wanted to open the economy, The Hill, the political insiders’ web site, reported, “Attorney General William Barr late Wednesday suggested that the federal government in May should begin relaxing some of the “draconian” social distancing restrictions imposed throughout the U.S.” Barr said in an interview with Fox News that the U.S. had to be very careful to ensure some of the measures being adopted are fully justified, and there are not alternative ways of protecting people amid the novel coronavirus outbreak, said the article, written by Justin Wise. (I assume Barr made his suggestion based on his medical training at Trump University’s health facility. I also don’t recall the president’s lawyer being concerned about the states ordered shut downs until Trump said it was time to reopen the economy. Just a coincidence, I assume.) Further down in the article by Wise: “The comments arrived as the number of confirmed cases of COVID-19, the illness caused by the novel coronavirus, continued to climb in the U.S. As of Thursday morning, the U.S. hadreported roughly 432,000 confirmed cases of the virus and more than 14,800 deaths from it.” (That was then. The numbers as I write at 4: 25 pm on April 26 are much worse now. According to CNN in the U.S: Infected 957016, deaths 54435.) In a Wall Street Journal April 21 Op-Ed column titled, “Seven Fateful Coronavirus Decisions,” national security advisor O’Brien’s opening paragraph said, “Facing a once-in-a-century pandemic, a crisis that some have likened to a world war, the U.S. is fortunate to have President Trump in charge. I have witnessed him make the tough decisions necessary at every turn to keep America safe. Seven of these decisions stand out.” (Google the Op-Ed to read the entire revisionist history article.) The Op-Ed concluded with O’Brien, or maybe his ghost scribe writing, “In my assessment, the president’s decisions outlined here have saved tens or even hundreds of thousands of American lives.
Load more

Recommended publications
  • Preparedness: Responding to Biological Attacks, Pandemics, and Emerging Infec- Tious Disease Outbreaks
    THE STATE OF U.S. PUBLIC HEALTH BIO- PREPAREDNESS: RESPONDING TO BIOLOGICAL ATTACKS, PANDEMICS, AND EMERGING INFEC- TIOUS DISEASE OUTBREAKS HEARING BEFORE THE SUBCOMMITTEE ON OVERSIGHT AND INVESTIGATIONS OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE OF REPRESENTATIVES ONE HUNDRED FIFTEENTH CONGRESS SECOND SESSION FRIDAY, JUNE 15, 2018 Serial No. 115–140 ( Printed for the use of the Committee on Energy and Commerce energycommerce.house.gov U.S. GOVERNMENT PUBLISHING OFFICE 35–127 WASHINGTON : 2019 VerDate Nov 24 2008 13:47 Feb 28, 2019 Jkt 037690 PO 00000 Frm 00001 Fmt 5011 Sfmt 5011 U:\MY DOCS\HEARINGS 115\HEARINGS\115-140 CHRIS COMMITTEE ON ENERGY AND COMMERCE GREG WALDEN, Oregon Chairman JOE BARTON, Texas FRANK PALLONE, JR., New Jersey Vice Chairman Ranking Member FRED UPTON, Michigan BOBBY L. RUSH, Illinois JOHN SHIMKUS, Illinois ANNA G. ESHOO, California MICHAEL C. BURGESS, Texas ELIOT L. ENGEL, New York MARSHA BLACKBURN, Tennessee GENE GREEN, Texas STEVE SCALISE, Louisiana DIANA DEGETTE, Colorado ROBERT E. LATTA, Ohio MICHAEL F. DOYLE, Pennsylvania CATHY MCMORRIS RODGERS, Washington JANICE D. SCHAKOWSKY, Illinois GREGG HARPER, Mississippi G.K. BUTTERFIELD, North Carolina LEONARD LANCE, New Jersey DORIS O. MATSUI, California BRETT GUTHRIE, Kentucky KATHY CASTOR, Florida PETE OLSON, Texas JOHN P. SARBANES, Maryland DAVID B. MCKINLEY, West Virginia JERRY MCNERNEY, California ADAM KINZINGER, Illinois PETER WELCH, Vermont H. MORGAN GRIFFITH, Virginia BEN RAY LUJA´ N, New Mexico GUS M. BILIRAKIS, Florida PAUL TONKO, New York BILL JOHNSON, Ohio YVETTE D. CLARKE, New York BILLY LONG, Missouri DAVID LOEBSACK, Iowa LARRY BUCSHON, Indiana KURT SCHRADER, Oregon BILL FLORES, Texas JOSEPH P.
    [Show full text]
  • A Few Problems I Have with Cable TV Political Reporting During the 2020 Presidential Election Season (Actually, Many Problems Would Be Truthful)
    A Few Problems I Have With Cable TV Political Reporting During The 2020 Presidential Election Season (Actually, Many Problems Would Be Truthful) (Author’s Note: This is the second in a series of occasional political columns that I’ll be writing for CommPRO.biz until Inauguration Day, January 20. Previously, I wrote 17 political columns leading up to Election Day. FYI – My first public relations job was with a political firm, where I worked on local, statewide and presidential campaigns. In this column, I opine why cable news political coverage is below par. The cut- off date for this article was to be the day of President Trump’s first presser after his election defeat, which was the day this was written, November 13,) Arthur Solomon Do cable news reporters mislead viewers because they don’t know the facts of what they are reporting? Or are they instructed to limit facts of a story by their producers to keep viewers’ interested and lure them back as a soap opera does for more? Or is it that the reporters and producers only read the first few paragraphs of the New York Times, Washington Post and Wall Street Journal for their stories,(in lieu of original reporting), which provides enough factual information for the usual headline type cable news report? In any event, what they report is too often incomplete or inaccurate, or even worse, simply pundits’ conjecturing as they attempt to show the audience how smart they are, when history shows – remember how their 2106 and 2020 Democratic wave elections turned out – the great majority of their gibberish is as accurate as Trump’s claim that the election was stolen from him.
    [Show full text]
  • Biden-Harris Transition Announces COVID-19 Advisory Board
    BIDEN-HARRIS TRANSITION The President-Elect The Vice President-Elect Priorities Transition Español NOVEMBER 09, 2020 PRESS RELEASES Biden-Harris Transition Announces COVID-19 Advisory Board Leading Public Health and Scientific Experts to Advise the Transition on COVID-19 Response WASHINGTON – Today, the Biden-Harris Transition announced the formation of the Transition COVID-19 Advisory Board, a team of leading public health experts who will advise President-elect Biden, Vice President-elect Harris, and the Transition’s COVID-19 staff. The Transition COVID-19 Advisory Board will be led by co-chairs Dr. David Kessler, Dr. Vivek Murthy, and Dr. Marcella Nunez-Smith. Dr. Beth Cameron and Dr. Rebecca Katz are serving as advisors to the Transition on COVID-19 and will work closely with the Advisory Board. “Dealing with the coronavirus pandemic is one of the most important battles our administration will face, and I will be informed by science and by experts,” said President-elect Biden. “The advisory board will help shape my approach to managing the surge in reported infections; ensuring vaccines are safe, effective, and distributed efficiently, equitably, and free; and protecting at-risk populations.” New cases are rising in at least 40 states, with more than 9.3 million total infections and more than 236,000 deaths. President-elect Biden has pledged to bring leadership to the COVID pandemic, which continues to claim thousands of lives each week, by curbing the spread of the disease, providing free treatment to those in need, and elevating the voices of scientists and public health experts. The COVID-19 Advisory Board will help guide the Biden-Harris Transition in planning for the President-elect’s robust federal response.
    [Show full text]
  • Bio's Virtual Summit Advances Medical Countermeasure
    BIO’S VIRTUAL SUMMIT ADVANCES MEDICAL COUNTERMEASURE PARTNERSHIPS FOR COVID-19 Launches Ongoing Initiative to Accelerate and Coordinate Development of Drugs, Vaccines, Preventives, and Diagnostics On March 24-25, 2020, BIO virtually convened more than 500 leaders from across industry, government, academia, and NGOs to assess the state of the pandemic and accelerate medical countermeasure solutions for COVID-19. BIO CEO Jim Greenwood and Dr. George Scangos, CEO of Vir, hosted the two-day summit to identify pressing technical, funding, regulatory and policy challenges, and enable BIO to catalyze cross- industry collaborations and public-private partnerships to advance development of medical countermeasures. Participants heard from key government officials, including Ambassador Deborah Birx, White House Coronavirus Response Coordinator, Dr. Robert Kadlec, HHS Assistant Secretary for Preparedness and Response, and Dr. Rick Bright, Director, Biomedical Advanced Research and Development Authority. KEY FINDINGS Based on Summit discussion, BIO identified the following critical needs and concerns: Successful development efforts will require the federal government to facilitate sharing of all relevant scientific and epidemiologic data and information as quickly and efficiently as possible. Many promising solutions will emerge from small and mid-sized companies and research laboratories, but these entities will likely have difficulty navigating the complex government contracting and regulatory bureaucracy; real-time assistance is needed. Early and rapid decisions from government funders will be essential to support immediate research, development, and clinical trial activity in order to identify the most promising candidates for further R&D and collaboration. Regulatory, advisory, and reimbursement authorities must be involved with requirement-setting and decision-making early on to prevent bottlenecks and downstream delays.
    [Show full text]
  • U.S. Role in the World: Background and Issues for Congress
    U.S. Role in the World: Background and Issues for Congress Ronald O'Rourke Specialist in Naval Affairs Michael Moodie Assistant Director and Senior Specialist in Foreign Affairs, Defense and Trade Updated February 24, 2020 Congressional Research Service 7-.... www.crs.gov R44891 U.S. Role in the World: Background and Issues for Congress Summary The U.S. role in the world refers to the overall character, purpose, or direction of U.S. participation in international affairs and the country’s overall relationship to the rest of the world. The U.S. role in the world can be viewed as establishing the overall context or framework for U.S. policymakers for developing, implementing, and measuring the success of U.S. policies and actions on specific international issues, and for foreign countries or other observers for interpreting and understanding U.S. actions on the world stage. While descriptions of the U.S. role in the world since the end of World War II vary in their specifics, it can be described in general terms as consisting of four key elements: global leadership; defense and promotion of the liberal international order; defense and promotion of freedom, democracy, and human rights; and prevention of the emergence of regional hegemons in Eurasia. The issue for Congress is whether the U.S. role in the world is changing, and if so, what implications this might have for the United States and the world. A change in the U.S. role could have significant and even profound effects on U.S. security, freedom, and prosperity. It could significantly affect U.S.
    [Show full text]
  • Key Global Health Positions and Officials in the U.S. Government
    January 2019 | Fact Sheet Key Global Health Positions and Officials in the U.S. Government Position Official WHITE HOUSE/EXECUTIVE OFFICE OF THE PRESIDENT Assistant to the President for National Security Affairs/National Security Advisor, National Security John Bolton Council (NSC) Senior Director for Weapons of Mass Destruction and Biodefense, NSC Tim Morrison Director for Medical and Biodefense Preparedness Policy, NSC Luciana Borio Director for Countering Biological Threats, NSC Hillary Carter Director for Global Health and International Development, NSC Peter Mamacos Special Assistant to the President; Senior Director for International Organizations and Alliances, Erin Walsh NSC Director, Office of Management and Budget (OMB) Mick Mulvaney Associate Director for National Security Programs, OMB Robert Blair Deputy Associate Director, International Affairs Division, National Security Programs, OMB Robert Fairweather Chief, Economic Affairs Branch, International Affairs Division, National Security Programs, OMB Fouad Saad Program Examiner, International Affairs Division, National Security Programs, OMB Will Cole Associate Director, Health Programs, OMB Joe Grogan Deputy Associate Director, Health Division, Health Programs, OMB Tom Reilly Chief, Public Health Branch, Health Programs, OMB Marc Garufi Program Examiner, Public Health Branch, Health Programs, OMB Nicholas Burton U.S. Trade Representative, Office of the United States Trade Representative (USTR) Robert Lighthizer Deputy U.S. Trade Representative, USTR C.J. Mahoney Assistant
    [Show full text]
  • Coalition for Epidemic Preparedness Innovations New Vaccines for a Safer World
    Coalition for Epidemic Preparedness Innovations New vaccines for a safer world Frederik Kristensen DCVMN Annual Meeting 25 October 2016 FOUNDING PARTNERS The challenge of epidemics Calls for global action CEPI - January - June Task Team Interim CEO High Level Task Team Leadership Meeting, Oslo appointed Meeting Tele- Group Meeting 6-7 April and constituted Davos conferences Washington DC Business Plan 21 January 17 May presented to stakeholders CEPI - July - September UNGA side Core Group First CEPI G7 Health event on health and CEPI soft interim board ministers’ side emergencies, Leadership launch meeting event, NY, Group Tele- Media London, Kobe, 19 September conferences coverage 31 August 10 September Challenges The pipeline is weak for most emerging infectious 1 diseases characterized by lack of market incentives Unilateral, uncoordinated government efforts to 2 fund R&D preparedness are inefficient and unsustainable in addressing global epidemic risks Clinical & regulatory pathways are not easily 3 adaptable to epidemic contexts Incentives are lacking to motivate 4 greater industry engagement Vaccine pipelines 45 40 35 30 25 20 15 10 5 0 Academic Government agency Biotech MNC Non-profits Preclinical Phase I Phase II Phase II/III Phase III Opportunities The Ebola momentum: vaccines are a feasible strategy, 1 despite a risky development pathway The Ebola momentum: it is possible to advance the 2 clinical development of safe and effective vaccines against EIDs in an emergency R&D actors supporting EID vaccine pipelines: 3 government health research agencies, academic research institutions, biotechs, vaccine manufacturers, and non-profits Manufacturing capability and capacity for vaccines has 4 always been a critical bottle-neck in epidemic events.
    [Show full text]
  • AKDN COVID-19 Policy Digest Bulletin #33 | Date: 16 November 2020 International Scientific Brief: Community Use of Cloth Mask
    1 AKDN COVID-19 Policy Digest Bulletin #33 | Date: 16 November 2020 International Scientific Brief: Community Use of Cloth Masks to Control the Spread of SARS-CoV-2 Centers for Disease Control and Prevention (CDC) https://www.cdc.gov/coronavirus/2019-ncov/more/masking-science-sars-cov2.html In a brief published on 10 November, the CDC recommends community use of masks, specifically non- valved multi-layer cloth masks, to prevent transmission of SARS-CoV-2. Masks are primarily intended to reduce the emission of virus-laden droplets (source control), which is especially relevant for asymptomatic or presymptomatic infected wearers who feel well and may be unaware of their infectiousness to others, and who are estimated to account for more than 50% of transmissions. Masks also help reduce inhalation of these droplets by the wearer (“filtration for personal protection”). The Johns Hopkins Center for Health Security explains that this guidance is noteworthy because masks can provide protection for the wearer as well, including the ability to filter “fine droplets and particles less than 10 micros.” Recent studies found that the filtration effect varied between masks and mask types, with multi-layer masks and mask types constructed with more densely woven material, preforming better than single-later masks made from lower thread count fabric. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19 U.S. Food and Drug Administration (FDA) https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes- monoclonal-antibody-treatment-covid-19 The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) on 9 November, for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and paediatric patients.
    [Show full text]
  • Chosen Nation: Christianity, Politics, and American Destiny" Dr
    TRANSCRIPT "Chosen Nation: Christianity, Politics, and American Destiny" Dr. Catherine Brekus Harvard Divinity School May 2017 MICHAEL CROMARTIE: Now let me just say, I will introduce our speaker. You've read her entire bio. I will not then read it back to you, simply to say that Professor Brekus, you may not know, was named the Harvard Divinity School Outstanding Teacher of the Year in 2014 and '15. She did her Ph.D. at Yale. Her undergrad was at Harvard, and on this topic some of you have never been here before. What we do is four months out, I meet with E.J. and Will and Karen and Andy Ferguson and others. We have a discussion about what should we be talking about at the next Faith Angle at the intersection of religion and public life, and I believe it was Will who said we really need to talk about religion and nationalism. One of our speakers at last Faith Angle, Grant Wacker, said the best person on this subject is our speaker today, and not only is she good on it, but she's writing a new book on it called Chosen Nation: Christianity and Politics in American Destiny. So when will your book be out? CATHERINE BREKUS: This is a wonderful opportunity for me, because I am going on sabbatical next year to work on this book. I have taught two courses about this and have written a little bit, but there is no publication date. MICHAEL CROMARTIE: But this is the trial run? CATHERINE BREKUS: This is a trial run.
    [Show full text]
  • COVID 19 Review Monografia N
    COVID 19 Review Monografia n. 5 Covid19 e i vaccini: i piani vaccinali e la logistica. A cura di Giorgio Banchieri, Antonio Giulio De Belvis, Maurizio Dal Maso, Lidia Goldoni, Stefania Mariantoni, Mario Ronchetti, Andrea Vannucci. Review realizzata in collaborazione con : 1 Nota redazionale. I materiali (articoli e dati) vengono selezionati da fonti accreditate: . Per gli articoli: The Lancet, British Medicine Journal, The New York Times, Science, Nature, Oxford Review, Cambridge Review, Quotidiano Sanità, Il Corriere della Sera, Il Sole 24Ore Sanità, La Repubblica e altri; Per le Istituzioni: . WH0/OMS, UE Centri di Prevenzione; OCDE, ONU, Protezione Civile, ISTAT, INAIL, Ministero Salute, ISS, AGENAS, CNR, Regioni, ARS, ASL, AO, AOP, IRCCS, Centri Studi e ricerche nazionali e internazionali e altri; Per i dati: . WH0/OMS, UE Centri di Prevenzione; OCDE, ONU, Protezione Civile, ISTAT, INAIL, Ministero Salute, ISS, AGENAS, CNR, Regioni, ARS, ASL, AO, AOP, IRCCS, Centri Studi e ricerche nazionali e internazionali e altri; Criteri di selezione: I materiali sono scelti in base ai seguenti criteri: Materiali di analisi recenti; Fonti accreditate; Tematiche inerenti a COVID19; Procedure internazionali e nazionali; Studi e ricerche epidemiologici; Studi su procedure per operatori sanitari e sociali; Linee Guida internazionali, nazionali e regionali; Linee Guida di società scientifiche e professionali. Le traduzioni sono fatte in automatico con il software “google” per rapidità di fruizione. Ci scusiamo se le traduzioni non sono sempre adeguate, ma riteniamo più utile la tempestività di divulgazione. Si ringraziano l’Editore COM SRL di Roma per il supporto Si ringrazia la Dr.ssa Giulia D’Allestro per il database repository.
    [Show full text]
  • Dr. Rick Bright, One of the Nation's Leading Experts in Pandemic
    THIRD ADDENDUM TO THE COMPLAINT OF PROHIBITED PERSONNEL PRACTICE AND OTHER PROHIBITED ACTIVITY BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES SUBMITTED BY DR. RICK BRIGHT I. Introduction Dr. Rick Bright, one of the nation’s leading experts in pandemic preparedness and response, and an internationally recognized expert in the fields of immunology, therapeutic intervention, and vaccine and diagnostic development, was abruptly removed from his position as Director of the Biomedical Advanced Research and Development Authority (“BARDA”) and transferred to a limited position at the National Institutes of Health (“NIH”) in retaliation for his whistleblowing activity under 5 U.S.C. § 2302(b)(8)(A). Specifically, and as detailed in his initial Complaint of Prohibited Personnel Practice filed with the Office of Special Counsel (“OSC”) on May 5, 2020, Secretary of Health and Human Services, Alex Azar, and other HHS political leaders engaged in an overtly hostile and career-derailing campaign of retaliation against Dr. Bright because he raised concerns about the Trump administration’s chaotic and reckless response to the COVID-19 pandemic. Shortly after cases of COVID-19 were identified in the United States, Dr. Bright sounded the alarm about the shortage of critical supplies, such as masks, respirators, swabs, and syringes that were necessary to combat COVID-19. In response, HHS political leadership leveled baseless criticisms against him and sidelined him because of his insistence that the Trump administration address these shortages and invest in vaccine development as well. Dr. Bright continued to speak out about the inevitable devastation that would be wrought by this virus at a time President Trump and his administration were intentionally lying to the American people about the serious threat posed by COVID-19 to the public health and safety.1 Dr.
    [Show full text]
  • Last Week, Rick Bright, the Former Director of the Biomedical Advanced Research and Development Authority (BARDA), Filed a Whistleblower Complaint with the U.S
    What the Bright Complaint Reveals about the Trump Administration’s COVID-19 Response Last week, Rick Bright, the former director of the Biomedical Advanced Research and Development Authority (BARDA), filed a whistleblower complaint with the U.S. Office of Special Counsel. Dr. Bright claims he was forced out from his role because he “insisted on scientifically-vetted proposals” and “pushed for a more aggressive agency response to COVID-19.” His allegations are shocking. Even in an Administration characterized by cronyism and incompetence, the failure of HHS political leadership to respond to COVID- 19 stands out. The Office of Special Counsel has already found “reasonable grounds to believe” that the Administration retaliated against Dr. Bright, and recommended that his removal be stayed while it investigates.1 His supervisor Robert Kadlec, the assistant secretary for preparedness and response (ASPR) at the Department of Health and Human Services, must step down. Given the multiple claims of political interference in the contracting process, HHS should fully disclose the terms of all contracts issued under Dr. Kadlec, and all evidence used to support contract awards. I. The Trump Administration Ignored Requests by Career Officials to Prepare for COVID-19. As early as January 10, 2020, Dr. Bright was urging HHS to dedicate appropriate resources to COVID-19. In response, “HHS political leadership leveled baseless criticisms against him for his proactive efforts to invest early in vaccine development as well as in critical supplies such as masks, respirators, and swabs, which were in short supply and would be necessary to combat COVID-19.”2 A Lack of Urgency: On January 18, Dr.
    [Show full text]